[1] Chhabra S, Narang T, Joshi N, et al. Circulating T-helper 17 cells and associated cytokines in psoriasis[J].Clin Exp Dermatol, 2016, 41(7):806-810. [2] de Oliveira PS, Pereira MC, Silva de Paula SK, et al. Increased IL17A, IFNG, and FOXP3 transcripts in moderate-severe psoriasis:A major influence exerted by IL17A in disease severity[J]. Mediators Inflamm, 2016, 2016:4395276. [3] Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells[J]. Nat Immunol, 2007, 8(9):942-949. [4] Fotiadou C, Lazaridou E, Sotiriou E, et al. IL-17A, IL-22, and IL-23 as Markers of Psoriasis Activity:A cross-sectional, hospital-based study[J]. J Cutan Med Surg, 2015, 19(6):555-560. [5] Xu Y, Xu X, Gao X, et al. Shikonin suppresses IL-17-induced VEGF expression via blockage of JAK2/STAT3 pathway[J]. Int Immunopharmacol, 2014, 19(2):327-333. [6] Xie XR, Zhang L, Liu X, et al. Effect of shikonin on proliferation of keratinocytes induced by interleukin-17 and expression of chemokines[J]. Zhongguo Zhong Yao Za Zhi, 2015, 40(5):946-949. [7] 行敏, 耿龙, 任宏伟, 等. 紫草素对IL-17刺激HaCaT细胞分泌VEGF影响的研究[J]. 中华微生物学和免疫学杂志, 2011, 31(8):685-688. [8] Antiga E, Volpi W, Cardilicchia E, et al. Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris[J].J Clin Immunol, 2012, 32(6):1221-1232. [9] AbuHilal M, Walsh S, Shear N.The Role of IL-17 in the pathogenesis of psoriasis and update on IL-17 inhibitors for the treatment of plaque psoriasis[J].J Cutan Med Surg, 2016, 20(6):509-516. [10] Muromoto R, Hirao T, Tawa K, et al.IL-17A plays a central role in the expression of psoriasis signature genes through the induction of IκB-ζ in keratinocytes[J].Int Immunol, 2016, 28(9):443-452. [11] Piskin G, Sylva-Steenland RM, Bos JD, et al. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions:enhanced expression in psoriatic skin[J]. J Immunol, 2006, 176(3):1908-1915. [12] Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells[J]. J Invest Dermatol, 2008, 128(5):1207-1211. [13] Johansen C, Usher PA, Kjellerup RB, et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin[J]. Br J Dermatol, 2009, 160(2):319-324. [14] de Oliveira PS, Cardoso PR, Lima EV, et al. IL-17A, IL-22, IL-6, and IL-21 Serum Levels in Plaque-Type Psoriasis in Brazilian Patients[J]. Mediators Inflamm, 2015,2015:819149. [15] 陈永锋, 常树霞, 郑道城. 寻常性银屑病患者外周血和皮损中Th17细胞及相关因子的表达[J]. 中华皮肤科杂志, 2011, 44(1):11-14. [16] Leonardi C, Matheson R, Zachariae C, et al.Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis[J]. N Engl J Med, 2012, 366(13):1190-1199. [17] 赵莎, 潘敏, 陈菲菲,等. 紫草素对银屑病样动物模型Th17细胞相关因子的影响[J]. 临床皮肤科杂志, 2016, 45(5):323-327. |